ERBB2 and lymphangioma: The biggest issue for the systemic treatment of HER2-positive LM patients is the need to overcome the blood–brain barrier, which is impervious to molecules with a molecular weight higher than 400–500 Da, thus limiting the efficacy of systemic treatment [19].